Actively Recruiting
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-09-05
246
Participants Needed
1
Research Sites
265 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.
CONDITIONS
Official Title
Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent has been obtained before any screening.
- Diagnosed with acinar adenocarcinoma, including neuro-endocrine dedifferentiation.
- Oligoprogressive disease with up to 3 extracranial progressive lesions confirmed by imaging within 6 weeks before randomization.
- Castration-refractory disease with testosterone level below 50 ng/dL.
- Prior treatment of the primary tumor by radiotherapy or surgery; untreated primary tumors must be treated within the trial.
- WHO performance status between 0 and 2.
- Age 18 years or older.
- No psychological, social, or geographical conditions that would make following the study difficult.
- Approved for inclusion by a multidisciplinary tumor board.
You will not qualify if you...
- Diagnosed with ductal adenocarcinoma or small-cell prostate cancer.
- Testosterone level above 50 ng/ml.
- More than 3 progressive lesions or poly-progressive disease on imaging.
- Presence of other active cancers that may affect trial results.
- Previous treatments or health conditions making stereotactic body radiation therapy impossible.
- Spinal bone lesions that are highly symptomatic, neurologically threatening, or at risk of fracture.
- Prior treatment with radionuclides, cabazitaxel, or PARP inhibitors.
- Disease progression while receiving docetaxel.
- Unable to understand the treatment plan or provide informed consent.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospitals Leuven
Leuven, Belgium
Actively Recruiting
Research Team
K
Kato Rans, MD
CONTACT
G
Gert De Meerleer, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here